Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
OABI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $4.96
Previous CloseN/A
Volume80.31K
Average Volume (3M)1.15M
Market Cap
$193.29M
Enterprise Value$169.82M
Total Cash (Recent Filing)$59.43M
Total Debt (Recent Filing)$23.16M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding122,335,335
10 Day Avg. Volume936,944
30 Day Avg. Volume1,151,656
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)0.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.05
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit39.58
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$7.67Price Target Upside385.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
OmniAb News
PremiumCompany Announcements
OmniAb’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
OmniAb Reports Steady Growth in Q1 2025PremiumCompany Announcements
OmniAb Appoints New Directors to Board---
Bulls Say, Bears Say
Bulls Say
PartnershipsOmniAb signed three licensing partnerships in the quarter, including ones with Wyss Institute at Harvard, Italy-based Takis Biotech, and Orion, also private, based in Finland.
Product LaunchThe new product launch, xPloration instrument, is seen as upside to 2025 estimates and is differentiated on its speed, scale, and its significant ease of use in antibody screening workflows.
Revenue StreamThe launch of the xPloration partner access program adds a new revenue stream, which can enhance the company's financial outlook.
Bears Say
Financial ConcernsQuestions about its $43M cash balance vs ~$38M FY25 cash burn remain, but management is confident the milestones in the post-discovery phase can get them to cash flow profitability.
Revenue ExpectationsOABI initiated guide at $20M-$25M, coming in below the Street's $46M and analyst's $33M, raising concerns about its financial outlook.
Service Revenue DeclineMilestone revenues were slightly offset by a -30% year-over-year decrease in Service revenues following completion of certain small molecule ion channel programs.
---
Ownership Overview
32.03% Insiders
19.45% Mutual Funds
2.79% Other Institutional Investors
36.86% Public Companies and Individual Investors
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.35 and its highest was $4.96 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $193.29M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Aug 07, 2025 which is in 79 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on May 08, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.006.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.15.
How many shares outstanding does OmniAb have?
OmniAb has 122,335,335 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went down -8.28%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
---
OmniAb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (385.44% Upside)
$7.67 (385.44% Upside)
Hedge Fund Trend
Increased
By 371.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $480.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.27%
12-Months-Change
Fundamentals
Return on Equity
-21.32%
Trailing 12-Months
Asset Growth
-13.15%
Trailing 12-Months
Company Description
OmniAb
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
---
OABI Company Deck
---
OABI Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for OmniAb with strong growth in deals and programs, a successful launch of a new product line, and increased revenue. However, challenges such as net losses and lower royalty revenues persist. Overall, the positives in terms of strategic growth and financial performance outweigh the negatives.Read More>---
OABI Stock 12 Month Forecast
Average Price Target
$7.67
▲(385.44% Upside)
Technical Analysis
---